LLY Jan 2026 690.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:01AM EDT. Market open.
| Previous close | 43.85 |
| Open | 43.85 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 690.00 |
| Expiry date | 2026-01-16 |
| Day's range | 43.85 - 43.85 |
| Contract range | N/A |
| Volume | |
| Open interest | 245 |
PR NewswireLilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. VIVID-1 is the first Phase 3 study for any approved or investigational treatment in Crohn's disease to report histologic and combined histologic-endoscopic outcomes that were evaluated using a systematic assessment of five bowel segments (fo
ZacksZacks Value Trader Highlights: Costco Wholesale, CAVA, Eli Lilly, Toll Brothers and Constellation Energy
Costco Wholesale, CAVA, Eli Lilly, Toll Brothers and Constellation Energy are part of the Zacks Value Trader article.
Yahoo Finance UKStarmer vows to slash red tape as UK investment summit begins
Companies such as Google parent Alphabet, BlackRock and Brookfield Asset Management are set to be in attendance.
© 2024 Yahoo. All rights reserved.